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SUMMARY
TFIIB-related factor 2 (Brf2) is a member of the family
of TFIIB-like core transcription factors. Brf2 recruits
RNApolymerase (Pol) III to type III gene-external pro-
moters, including the U6 spliceosomal RNA and sele-
nocysteine tRNA genes. Found only in vertebrates,
Brf2 has been linked to tumorigenesis but the under-
lying mechanisms remain elusive. We have solved
crystal structures of a human Brf2-TBP complex
bound to natural promoters, obtaining a detailed
view of the molecular interactions occurring at Brf2-
dependent Pol III promoters and highlighting the
general structural and functional conservation of
human Pol II and Pol III pre-initiation complexes. Sur-
prisingly, our structural and functional studies
unravel a Brf2 redox-sensingmodule capable of spe-
cifically regulating Pol III transcriptional output in
living cells. Furthermore, we establish Brf2 as a cen-
tral redox-sensing transcription factor involved in the
oxidative stress pathway and provide a mechanistic
model for Brf2 genetic activation in lung and breast
cancer.
INTRODUCTION
In the eukaryotic nucleus, RNA polymerase (Pol) III transcribes
genes encoding essential RNAs, including tRNAs and the 5S
rRNA. The accurate recruitment of Pol III to its target genes
and the formation of a transcriptionally active pre-initiation
complex (PIC) occur through the association of Pol III with
several specific transcription factors but TFIIIB is the key factor
required for this process (Kassavetis et al., 1999; Schramm
and Hernandez, 2002). TFIIIB is a complex composed of the
TFIIB-related factor 1 (Brf1) (Lo´pez-De-Leo´n et al., 1992;
Wang and Roeder, 1995), the TATA binding protein (TBP) (Kas-
savetis et al., 1992; Lobo et al., 1992), and Bdp1, a SANT
domain-containing protein (Kassavetis et al., 1995; Schramm
et al., 2000). Vertebrates contain an alternative TFIIIB complex
in which Brf1 is replaced by the TFIIB-related factor 2 (Brf2)
(Cabart and Murphy, 2001; Schramm et al., 2000; Teichmann
et al., 2000).
The Brf2-containing TFIIIB complex recruits Pol III to type III
promoters, characterized by a TATA box located 20–25 base
pairs (bp) upstreamof the transcriptional start site and a proximal
sequence element (PSE) located further upstream (Schramm
and Hernandez, 2002). The TATA box is recognized by the
Brf2-TBP complex, which binds synergistically with SNAPc, a
complex binding to the PSE (Henry et al., 1995). Actively tran-
scribed Brf2-dependent genes have been characterized
genome-wide (Carrie`re et al., 2012; James Faresse et al.,
2012; Oler et al., 2010) and encode a small collection of RNAs
including the spliceosomal U6 small nuclear RNA (snRNA), the
RNA component of the tRNA processing enzyme RNase P,
and the selenocysteine tRNA (Table S1).
Brf2 and Brf1 are part of a family of TFIIB-like transcription fac-
tors that share structural and functional features with the arche-
typal Pol II transcription factor TFIIB (Knutson and Hahn, 2011;
Naidu et al., 2011; Vannini and Cramer, 2012). These factors all
contain an N-terminal B-ribbon/reader/linker domain, which pro-
trudes toward the polymerase active site, and a B-core domain
consisting of two cyclin fold imperfect repeats, which in TFIIB
binds simultaneously to the core of the Pol II enzyme, TBP,
and the DNA. Additionally, Brf2 and Brf1 contain C-terminal do-
mains (CTDs), which represent the major site of interaction with
the adjoining TFIIIB subunits Bdp1 and TBP (Saxena et al., 2005).
Whether TFIIB-like factors display the same architecture as
TFIIB when bound to TBP and DNA is currently not known.
Pol III transcription is tightly regulated during the cell-cycle and
its upregulation has been linked to tumorigenesis (White, 2011).
Recently, Brf2 was found to be specifically amplified in the squa-
mous cell carcinoma subtype of non-small cell lung cancer
(Lockwood et al., 2010). Additionally, Brf2 overexpression is
observed in several forms of cancers and correlates with poor
patient survival rates, implicating Brf2 as a general oncogene,
a prognosis marker, and a target for new anticancer therapies
(Cabarcas and Schramm, 2011; Lu et al., 2013, 2014). Despite
its significance, very little is known about the molecular architec-
ture and mechanisms underlying Brf2-dependent Pol III tran-
scription and its regulation.
RESULTS
Architecture of Brf2-TBP/DNA Complexes
We obtained X-ray crystallographic structures of Brf2-TBP com-
plexes bound to the U6 snRNA (copy number 2, U6-2), RPPH1,
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and TRNAU1 promoters at resolutions of 1.9 A˚, 2.2 A˚, and 2.7 A˚,
respectively (Figures 1A and S1A–S1D; Table S2). In all three
cases, the double-stranded DNA scaffold used for crystallization
was 28 bp long and corresponded to promoter sequences
extending 10 bp upstream and downstream of the TATA box
(Figure S1A). Notably, the DNA path was not perturbed by the
crystalline environment and was influenced only by the specific
interactions with TBP and Brf2. Where not stated otherwise,
we focus on the analysis of the complex solved at the highest
resolution, the Brf2-TBP/U6-2 complex (hereafter referred to
as the Brf2-TBP/DNA complex), but the conclusions apply to
all three complexes.
The overall architecture of the Brf2-TBP/DNA complex (Fig-
ure 1) is reminiscent of the TFIIB-TBP/DNA complex (Nikolov
et al., 1995; Tsai and Sigler, 2000), thus providing experimental
support to the proposed common architectural organization of
TFIIB-related factors and TFIIB (Vannini and Cramer, 2012) (Fig-
ure S1B). In the Brf2-TBP/RPPH1 structure, the Brf2-TBP com-
plex is bound to the DNA with inverse polarity, probably due to
the perfect dyad symmetry of the TATA box at this promoter (Fig-
ures S1A and S1C).
Whether associated with Brf2 or TFIIB, TBP interacts with the
TATA box in an undistinguishable manner, generating a virtually
identical local bend in the DNA. However, as a result of specific
Brf2/DNA interactions, the path of the DNA backbone deviates at
the TATA flanking regions (Figure S1B). Modeling of a Pol III
closed PIC using the Brf2-TBP/DNA complex revealed no
clashes with the polymerase core and a DNA path that strongly
resembles that of the human Pol II closed PIC (He et al., 2013)
(Figure 2). In this model, the path of the DNA downstream of
the TATA box points directly toward the Pol III subunits C39
and C62, consistent with their DNA binding activity and their
functional role in DNA melting and open PIC stabilization (Brun
et al., 1997; Lefe`vre et al., 2011).
Brf2/DNA-Specific Interactions
Brf2 contacts extensively the phosphate backbone of the DNA
and establishes sequence-specific contacts with both the
upstream and downstream TATA flanking regions (Figures 1A
and S1A–S1C). The Brf2 N-terminal cyclin repeat is structurally
related to the corresponding domain in TFIIB, however in the
Brf2-TBP/DNA complex the minor groove of the DNA is more
intimately contacted via a helix-turn-helix motif (Figures 1A and
3A). The highly conserved dyad K113 and K114 (Figure S1E)
contacts the phosphate backbone of the DNA on opposite sides,
allowing the insertion of a short helix into the minor groove and
the consequent direct recognition of bases A+3 and G
0
+4
(numbering is relative to the edge of the TATA box, with the
non-template strand designated by a prime) (Figure 3A). The
side chain of R110 forms a direct hydrogen bond with A+3 and
a water-mediated hydrogen bond with G0+4, whereas the main
chain carbonyl oxygen of A108 forms a direct hydrogen bond
Figure 1. Structure of the Brf2-TBP/DNA Ternary Complex
(A) Overview of the Brf2-TBP/U6 promoter structure. DNA template and non-template strands are in blue and cyan respectively. Dashed lines represent
disordered regions or regions not present in the crystallization construct.
(B) Schematic of Brf2 domain organization.
See also Figures S1, S2, and S7 and Tables S1 and S2.
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with G0+4. These interactions locally distort the DNA, leaving the
base T0+3 unstacked at its downstream edge. A nucleobase T at
position +3 on the non-template strand, followed by a nucleo-
base A, T, or G (collectively abbreviated as D) at position +4, is
notably enriched at Brf2-dependent promoters (Figure S2A).
We investigated the importance of the TD motif, which is also a
conserved feature of the Pol II BREd (Deng and Roberts, 2005),
on the formation of a Brf2-TBP/DNA ternary complex, using
electrophoretic mobility shift assays (EMSAs) (Figure 3B). In
agreement with the observed role of R110 in specific recognition
of A+3, a Brf2 R110Amutant displayed a reduced affinity for DNA
compared to Brf2wild-type, an effect that wasmost prominent in
presence of an A nucleobase at position +3 of the template
strand, suggesting a functional discrimination between T0+3
-containing and T0+3 -less promoters (Figures 3B and S2A).
Thus, the conserved TD element, a dinucleotide step character-
ized by low unstacking energies (Protozanova et al., 2004), may
represent a site at the downstream edge of the TATA box where
DNAmelting is favored as a result of the specific interactions with
Brf2 R110 and A108. Indeed, in the Brf2-TBP/RPPH1 structure,
in which the canonical TDmotif is replacedwith TC nucleobases,
the T0+3C0+4 dinucleotide is still specifically recognized by R110
but with an altered set of interactions that leaves the nucleobase
T0+3 unperturbed and regularly stacked at both edges, likely due
to the higher stacking energy of this dinucleotide step
(Figure S2C).
The Brf2 C-terminal cyclin repeat interacts with the major
groove upstream of the TATA-box, similarly to TFIIB albeit
more intimately (Lagrange et al., 1998; Tsai and Sigler, 2000)
(Figures 1A and 3C). Brf2 residue Y260 establishes a hydrogen
bond and a T-shaped p-p interaction with nucleobase C4 and
an additional T-shaped p-p interaction with nucleobase C3
(Figure 3C). T-shaped p-p interactions are favored in the pres-
ence of pyrimidines (Wilson et al., 2014), explaining their enrich-
ment, in particular for C, observed at 4 and 3 positions
(Figure S2A). The hydrogen bond between Y260 and C4 ex-
plains the presence of a C4 nucleobase (complementary G in
the non-template strand) at the vast majority of Brf2-dependent
promoters, since a base-specific hydrogen bond is only possible
with the amine group of a pyrimidine nucleobase C or purine nu-
cleobase A at that position. Indeed, substitution of C4 with a
G or a T residue, or exchange of both adjacent pyrimidines
with purines, resulted in reduced binding (Figure 3D). A nucleo-
base A at position 4 is well tolerated since it can establish an
hydrogen bond with Y260, but exclusively in presence of a
pyrimidine at position 3, in order to preserve the additional
p-p interaction. In summary, the structural and functional data
underscore the preference for a C nucleobase and a pyrimidine
nucleobase (C or T) at positions 4 and 3, respectively, of the
template strand. We named this Brf2-specific dinucleotide step
the ‘‘GR’’ element (Figure S2A).
Modular Architecture of Brf2 CTD
The Brf2 CTD is organized into three conserved modular struc-
tural elements (Figures 1 and S1E). Brf2 conserved residues
291–314 fold into an unusual semi-circular a helix, which we
named the ‘‘arch.’’ Brf2 truncation at position D289, but not at
positions R394, G380, G348, or A311, prevented the formation
of a SNAPc-Brf2-TBP/DNA complex (Figure S3A), consistent
with the arch constituting a main SNAPc-binding interface.
The C-terminal part of the Brf2 CTD (residues 374–419) folds
into a TBP ‘‘anchor domain,’’ which structurally resembles Brf1
Figure 2. Architecture of the Human Pol III PIC
Model of a Pol III PIC (Vannini and Cramer, 2012) generated using the Brf2-TBP/DNA complex reveals that the path of the downstream DNA points toward the Pol
III-specific subunits C39 and C62, and resembles the path observed in yeast and human Pol II PIC (He et al., 2013; Mu¨hlbacher et al., 2014).
See also Figure S7.
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Figure 3. Brf2/DNA Sequence-Specific Interactions
(A) Close-up view of the TATA box (yellow), downstream flanking region and sequence-specific interactions with Brf2. DNA template and non-template strands
are in blue and cyan respectively.
(B) Substitutions at positions +3 and +4 of the wild-type (circled in red) U6-2 promoter decrease binding of a R110A mutant, in particular when a T nucleobase is
present at position +3 on the non-template strand (in cyan). R110A versus wild-type (WT) is the ratio between the percentage of binding of themutant versus wild-
type Brf2 proteins.
(C) Close-up view of the TATA box (yellow), upstream flanking region and sequence-specific interactionswith Brf2. DNA template and non-template strands are in
blue and cyan respectively.
(D) Substitutions at positions3 and4 of the wild-type (circled in red) U6-2 promoter reveal more efficient complex formation with a pyrimidine nucleobase and
a C nucleobase at positions3 and4 of the template strand, respectively. (B and D) The intensity of the complex formed with TBP, U6-2 nonmutated sequence
and wild-type Brf2 (lane 1) was used as a reference for relative quantification. *Indicates samples that were quantified relative to a distinct wild-type sequence
reference not shown on the figure. Representative gels of three independent experiments. The data shown are the mean values and SE of three independent
experiments. In the insets, 10 ml of a typical binding reaction (25 ml total) with Brf2 wild-type or Brf2 mutants were loaded on a SDS-PAGE gel and stained with
Coomassie-blue, confirming that equal amounts of protein of comparable quality were used for EMSA assays.
See also Figures S2 and S7.
1378 Cell 163, 1375–1387, December 3, 2015 ª2015 The Authors
homology region II and binds TBP on its convex surface similarly
to other TBP-associated factors (Anandapadamanaban et al.,
2013; Juo et al., 2003) (Figure S3B). Remarkably, deletion of
the TBP anchor domain (residues 365–419) not only abolishes
the binding of Brf2 to TBP but also abrogates the formation of
a ternary Brf2-TBP/DNA complex (Figures 4A and 4B).
A Brf2-specific short structured element (residues 357–363),
the ‘‘molecular pin,’’ encompasses a conserved LPPC motif
and lies at the ternary interface between the Brf2 C-terminal cy-
clin repeat, TBP, and the DNA (Figure S1E and Figure 4C). This
helical element virtually pins the ternary complex together, juxta-
posing onto a hydrophobic pocket at the interface between TBP
and the Brf2 C-terminal cyclin repeat, which, in contrast to what
is observed for TFIIB, strongly interact together. The Brf2 residue
W215 forms a hydrophobic stack with TBP residues R269 and
P267 (Figure 4C) and is conserved throughout Brf2 evolution
and in human and yeast Brf1, implying a conserved general ar-
chitecture of Pol III Brf1- and Brf2-TBP complexes (Figures
S1E and S2B). These additional strong interactions between
the Brf2 and Brf1 C-terminal cyclin repeats and TBP may
contribute to the observed increased stability of the Pol III-PIC,
as compared to Pol II (Arimbasseri et al., 2013). The deletion of
the molecular pin does not impair Brf2 binding to TBP in the
absence of DNA but severely impairs the formation of a ternary
complex, underscoring the central role of the molecular pin in
the formation of a functional Brf2-TBP/DNA complex (Figures
4A and 4B). At the tip of the molecular pin, the Brf2 residue
C361 is buried in the groove between two adjacent phosphate
groups of the DNA backbone, establishing both van der Waals
and water-mediated hydrogen bonds at the upstream edge of
the TATA box (Figure 5A).
Brf2 Is Redox Regulated
A recurring theme in redox signaling by transcription factors is
the presence of a reactive cysteine thiol that can cycle through
reduced and oxidized states, ‘‘sensing’’ the redox environment
of the cell (Brigelius-Flohe and Flohe, 2011). We noticed a
remarkable structural similarity between the conserved Brf2
C361 and NF-kB p50 C59 (Ghosh et al., 1995) (Figure S3C), a
DNA-binding cysteine residue regulated via oxidative modifica-
tions in vivo (Pineda-Molina et al., 2001), prompting us to inves-
tigate the redox properties of Brf2.
Using tandemmass-spectrometry, we could detect reversible
oxidative modifications of C361 upon overnight incubation of
Brf2 in absence of reducing agents and in presence of dime-
done, a cyclic diketone that specifically reacts with sulfenic
acid (Figure S4). The strictly conserved C361 and the nearby
non-conserved C370 were the only two cysteine residues clearly
identified with bound dimedone, suggesting that these residues
reside in a local protein environment prone to oxidation. Indeed,
the chemical environment surrounding these residues is en-
riched in positively charged residues (K363, K367, and R368),
Figure 4. The Brf2 Molecular Pin
(A) The Brf2 TBP anchor domain but not the molecular pin is essential for
Brf2-TBP interaction in absence of the DNA, as shown by a pull-down
assay.
(B) The Brf2 TBP anchor domain and the molecular pin are essential for the
formation of a Brf2-TBP/DNA complex, as shown in an EMSA.
(C) Close-up view of the Brf2 molecular pin at the interface between the Brf2
C-cyclin repeat, TBP, and the DNA.
See also Figures S3 and S7.
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which are known to stabilize thiolate anions, reducing the pKa of
the cysteine residues and thus resulting in a sulfur atom that is
more susceptible to oxidation (Lo Conte and Carroll, 2013). Pro-
tein sulfenylation is a reversible post-translational modification
that is emerging as a novel regulatory mechanism with particular
relevance in redox signal transduction (Gupta and Carroll, 2014).
In this context, the formation of mixed disulfide bonds between
sulfenic acid intermediates and low molecular-weight thiols
such as glutathione constitutes a common cellular mechanism to
prevent progression toward irreversible oxidation states, thus
ensuring reversible regulation. We confirmed by tandem mass-
spectrometry that upon incubation with oxidized glutathione,
Brf2 is efficiently S-glutathionylated specifically at residues
C361 and C370 (Figure S4). Altogether, the mass-spectrometry
Figure 5. Brf2 Redox Regulation
(A) Close-up view of C361 at the ternary interface between the Brf2 C-cyclin repeat, TBP, and the upstream edge of the TATA box. Yellow dots represent the van
der Waals radius of the sulfur atom.
(B) Representative EMSA of Brf2-TBP/DNA complexes upon pre-incubation of Brf2 proteins with the alkylating agent iodoacetamide. The IC band was used for
loading normalization. *Indicates addition of the reducing agent after the oxidative treatment during complex assembly.
(C) Representative EMSA of Brf2-TBP/DNA complexes upon removal of reducing agent (DTT) and incubation over time. The IC band was used for loading
normalization. *Indicates addition of the reducing agent after the oxidative treatment during complex assembly.
(D) Representative EMSA of Brf2-TBP/DNA complexes upon pre-incubation of Brf2 proteins with H2O2. The IC band was used for loading normalization.
*Indicates addition of the reducing agent after the oxidative treatment during complex assembly.
(E) Representative EMSA of Brf2-TBP/DNA complexes upon pre-incubation of Brf2 proteins with gradients of oxidized/reduced glutathione (GSSG:GSH). The IC
band was used for loading normalization. *Indicates addition of the reducing agent after the oxidative treatment during complex assembly.
See also Figures S3, S4, and S7.
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data indicate that Brf2 C361 and C370 are highly reactive
cysteine residues that are prone to oxidation and can be S-glu-
tathionylated in vitro.
We thus tested the functional relevance of Brf2 oxidative
modifications on the formation of functional Brf2-TBP/DNA
complexes using EMSAs. Incubation of Brf2 with iodoaceta-
mide, a low molecular-weight compound that irreversibly alkyl-
ates reactive cysteine and lysine residues in proteins and
peptides, resulted in a severe reduction of Brf2-TBP/DNA com-
plex assembly (Figure 5B). This effect was mediated by residue
C361, since a Brf2 C361A mutant was insensitive to treatments
with the alkylating agent and displayed unaltered affinity for
TBP/DNA complexes (Figure 5B and S3F). Thus, out of a total
of 16 cysteine residues, Brf2 C361 is the sole reactive cysteine
negatively regulating the formation of the Brf2-TBP/DNA
ternary complex upon alkylation. Brf2 oxidation caused by
removal of reducing agents and incubation over time impaired
the formation of the ternary complex, an effect that was mostly
reversible and mediated by C361 (Figure 5C). This finding sug-
gests that oxidative modifications of C361 can reversibly
modulate the assembly of the ternary complex and that a
C361A mutation can confer redox-insensitivity to Brf2. In
agreement, incubation of wild-type Brf2 with low concentra-
tions of H2O2 also impaired the formation of the complex, while
the C361A mutant remained insensitive (Figure 5D), suggesting
that Brf2 C361 is susceptible to regulation by reactive oxygen
species (ROS). Moreover, a Brf2 C361D mutant, structurally
mimicking the oxidation state of C361 as a cysteic acid, was
compromised in ternary complex formation with an apparent
50-fold reduction in affinity for TBP-DNA complexes, while still
capable of efficiently binding to TBP (Figures S3D–S3F). To
better simulate the perturbations of the redox potential that
occur during oxidative stress in the cell, we treated Brf2 with
gradients of oxidized/reduced glutathione (GSSG/GSH), whose
ratio increases drastically during oxidative stress (Jones, 2006).
The formation of the ternary complex was highly sensitive to
Brf2 treatments with GSSG/GSH, an effect that was fully
reversed by addition of reducing agents and again exclusively
mediated by C361, since the C361A mutant was insensitive
to treatments with high GSSG/GSH ratios (Figure 5E).
Collectively, these results support a redox-sensing functional
role of Brf2 C361, whose critical localization at the Brf2-TBP/
DNA ternary interface enables modulation of the assembly of a
functional complex.
Brf2-Dependent Pol III Transcription Is Redox-
Regulated in Living Cells
Having established Brf2 as a bona fide redox sensor, we asked
whether synthesis of Brf2-dependent RNAs might be regulated
in response to oxidative stress in living cells. We monitored the
intracellular levels of Brf2-dependent transcripts by qRT-PCR in
MRC5 lung fibroblast cells challenged by exposure to tert-bu-
tylhydroperoxide (t-BHP), a potent inducer of oxidative stress.
Remarkably, all the Brf2-dependent transcripts tested were
severely reduced upon treatment, while leucine tRNA pre-
cursors (p-tRNA), a Brf1-dependent transcript, remained un-
changed (Figure 6A). We then focused on the selenocysteine
(SeCys) tRNA, an essential tRNA encoded by a single active
gene in mammalian genomes (James Faresse et al., 2012;
Oler et al., 2010). Intracellular levels of SeCys p-tRNA were
severely reduced in a t-BHP concentration- and exposure
time-dependent manner (Figure 6B). Removal of the oxidative
agent after an acute exposure promptly restored high levels
of SeCys p-tRNA (Figure 6C). Importantly, oxidative stress-
induced decrease of SeCys p-tRNA was Brf2-dependent, since
transient transfection with Brf2 overexpression vectors rescued
this effect (Figure 6D). Strikingly, overexpression of the Brf2
redox-insensitive C361A mutant led to an increase of SeCys
p-tRNA, suggesting the loss of a negative regulatory step.
Conversely, overexpression of the Brf2 oxidized-mimic C361D
did not affect SeCys p-tRNA, suggesting that this mutant is
virtually inactive (Figure 6D). In agreement with the existence
of a post-translational regulatory mechanism, the decrease of
SeCys p-tRNA levels observed upon treatment of MRC5 cells
with t-BHP did not correlate with reduced Brf2 expression
levels, which in fact increased during oxidative stress (Fig-
ure 7A). Furthermore, we observed an 80% reduction of SeCys
mature tRNA (m-tRNA) levels in cells challenged with t-BHP, an
effect that was reversed by overexpression of Brf2 (Figure S5A).
Despite tRNAs generally being considered as molecules with a
relatively long half-life, this result is in agreement with previ-
ously published data highlighting the higher rate of decay of
SeCys tRNA when compared to other tRNAs (Jameson et al.,
2002).
Redox Sensing by Brf2 Modulates Resistance to
Oxidative Stress in Normal and Cancer Cells
SeCys tRNA is essential for the synthesis of selenoproteins, the
vast majority of which are involved in ROS detoxification and in
the maintenance of cellular redox homeostasis (Kasaikina et al.,
2012). To test whether the observed Brf2-dependent reduction
of SeCys tRNA levels upon oxidative stress can impact the syn-
thesis of selenoproteins and, consequently, resistance to ROS,
we monitored the expression levels of a group of selenopro-
teins (Gpx1, Gpx4, SelM, and Sep15) in which a SeCys residue
is present toward the N terminus of the protein (Kasaikina et al.,
2012). In conditions of oxidative stress, as monitored by the
increased steady-state levels of the nuclear factor erythroid
2-related factor 2 (Nrf2), intracellular levels of all the selenopro-
teins tested were substantially reduced in MRC5 cells, an effect
that was rescued by overexpression of Brf2, while no differ-
ences were observed in unchallenged cells (Figure 7A). Strik-
ingly, Brf2 overexpression in MRC5 cells resulted in a marked
acquired resistance toward oxidative stress enabling MRC5
cells to evade apoptosis (Figure 7B). Paralleling the redox-
induced changes in SeCys p-tRNA synthesis, overexpression
of the Brf2 redox-insensitive C361A mutant enabled a more
pronounced resistance to oxidative stress when compared to
Brf2 wild-type, while the Brf2 oxidized-mimic C361D was
severely impaired in conferring resistance to apoptosis (Fig-
ure 7C). Since Brf2 has been recently discovered as a top-
scoring candidate driver in breast carcinomas (Sanchez-Garcia
et al., 2014), we additionally investigated the effects of Brf2
overexpression on selenoproteins expression levels and
evasion of apoptosis in MCF10A cells, a mammary epithelium
cell line with low expression of Brf2. We observed a strong
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acquired resistance to oxidative stress that correlates with
higher levels of selenoproteins, analogously to what observed
in MRC5 cells (Figures S5B–S5D).
Conversely, to test the functional consequences of decreasing
Brf2 activity during oxidative stress in cancer cells, we reduced
the levels of Brf2 via small interfering RNA (siRNA) in A549 cells
challenged with t-BHP. A549 are epithelial human lung adeno-
carcinoma cells displaying high Brf2 expression and a generally
increased resistance to t-BHP treatment when compared to
MRC5 fibroblasts (Figures 7A and 7D). In A549 cells, we could
additionally monitor the expression levels of Gpx2, a selenopro-
tein upregulated by Nrf2 during oxidative stress (Brigelius-Flohe´
et al., 2012) and overexpressed in colorectal and prostate cancer
(Emmink et al., 2014; Naiki et al., 2014). As for the primary cell
lines, we observed an inverse correlation between cellular
commitment to apoptosis and the expression level of selenopro-
teins (Figures 7A and 7D). Levels of all the selenoproteins tested,
including Gpx2 that was upregulated during oxidative stress,
were reduced in Brf2-silenced cells challenged with 50 mM
t-BHP, a condition that induced apoptosis (Figures 7A and 7D).
This effect, as well as the decrease of SeCys p-tRNA levels,
was reversed by concomitant overexpression of a siRNA-resis-
tant form of Brf2 (Figure S6), suggesting a direct involvement
of Brf2 in the oxidative stress response pathway and in the
acquired resistance to oxidative stress observed in human lung
adenocarcinoma cells.
Figure 6. Brf2-Dependent Transcription Is Redox Regulated in Living Cells
(A) qRT-PCR analysis shows that Brf2-dependent-transcripts (SeCys p-tRNA, RPPH1, RNA7SK, and U6 snRNA) are globally downregulated during oxidative
stress, while a Brf1-dependent transcript (Leu p-tRNA) remains unchanged.
(B) SeCys p-tRNA levels are strongly reduced in cells challengedwith t-BHP relative to the unchallenged cells (as highlighted by gray and black lines, respectively)
in a dose- and time-dependent manner, as measured by qRT-PCR.
(C) SeCys p-tRNA levels rapidly recover upon removal of the exogenous oxidative stress inducer, as measured by qRT-PCR. Wash indicates replacement of
media containing t-BHP with fresh media.
(D) Effects of overexpression of Brf2 and Brf2 mutants (inset) on SeCys p-tRNA levels during oxidative stress, as measured by qRT-PCR.
The numbers indicated on the histograms represent the percentage of reduction of selenocysteine tRNA levels, while if numbers are indicated above the his-
tograms they represent the percentage of increase. Cumulative data of at least three experiments, mean + SEM. Unpaired t test: *p < 0.05; **p < 0.005;
***p < 0.0005; ****p < 0.0001. p > 0.05 were deemed not significant and values were not reported.
See also Figures S5 and S7.
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DISCUSSION
The structures of Brf2-TBP/DNA ternary complexes reveal a
general conservation of the architecture of TFIIB-related factors
and specific recognition of DNA elements by Brf2. A TD element
at the downstream edge of the TATA box, a central component
of the BREd Pol II core promoter element (Deng and Roberts,
2005), is specifically recognized by a Brf2 minor groove interact-
ing element, resulting in a local distortion of the nucleic acid
structure and a partially unstacked T nucleobase (Figures 2,
3A, and S2C), suggesting that BREd and BREd-like elements
could represent sites primed for DNA melting. In this respect,
the winged helix domains of yeast Pol III subunit C34 and Pol II
transcription factor TFIIF (Tfg2 subunit), which have been
involved in open complex formation and/or its stabilization
(Brun et al., 1997; Mu¨hlbacher et al., 2014), have been located
exactly opposite of this site by cross-linking coupled with
mass-spectrometry (Mu¨hlbacher et al., 2014; Wu et al., 2012).
A completely unexpected finding was the discovery of a
redox-sensing regulatory module embedded in a TFIIB-related
core transcription factor, implying a direct redox-dependent
control of a eukaryotic nuclear RNA polymerase. Fewer than
20 Brf2-dependent genes are actively transcribed in mammalian
cells, but their products are all involved in key functions (Table
S1).We have focused on the SeCys tRNA gene, since selenopro-
teins are directly involved in the oxidative stress response. We
discovered that levels of SeCys tRNAs and selenoproteins are
strongly reduced during oxidative stress in living cells in a Brf2-
dependent manner, and this effect is inversely correlated with
oxidative stress-induced apoptosis (Figures 6, 7, and S5).
Abrogating selenoprotein expression or expression of trun-
cated selenoproteins induces apoptotic cellular death, sensitiza-
tion toward oxidative stress and a reversion of the cancerous
phenotype (Anestal et al., 2008; Emmink et al., 2014; Yoo
et al., 2013). Reduced selenoprotein expression or generation
of defective truncated selenoproteins might occur upon pro-
longed activation of the Nrf2 pathway, which upregulate the syn-
thesis of TrxR1 and Gpx2 mRNAs, in conjunction with limited
intracellular amounts of SeCys tRNAs. Indeed, we show that
levels of Secys p-tRNAs, SeCys m-tRNAs and selenoproteins
are reduced during prolonged oxidative stress in a Brf2-depen-
dent manner (Figures 6A, 6B, 7A, S5A, and S5C). Thus, Brf2
redox-dependent regulation constitutes a cellular blockade
capable of generating pro-apoptotic signals upon prolonged
oxidative stress, by limiting the availability of SeCys tRNA
(Figure S7).
Redox-dependent activation of Nrf2 is one of the principal
events of the oxidative stress response pathway and is constitu-
tively activated in squamous cell lung and breast carcinomas
(Brigelius-Flohe´ et al., 2012; Cancer Genome Atlas Research
Network, 2012; Sjo¨blom et al., 2006). Major targets upregulated
by Nrf2 upon oxidative stress include TrxR1 and Gpx2, two
essential selenoproteins involved in the maintenance of redox
homeostasis and anti-oxidant defense, which are found overex-
pressed in several forms of cancers (Biaglow and Miller, 2005;
Brigelius-Flohe´ et al., 2012; Emmink et al., 2014; Naiki et al.,
2014). Thus, we hypothesized that overexpression of Brf2, which
is also observed in many forms of cancer (Cabarcas and
Schramm, 2011), is required to overcome the Brf2-dependent
reduction of SeCys tRNAs observed during prolonged oxidative
stress, in order to maintain sufficient expression levels of seleno-
proteins required for ROS detoxification and redox homeostasis.
In agreement with this model, reducing Brf2 protein levels in
A549 lung adenocarcinoma cells via siRNA resulted in dimin-
ished levels of selenoproteins (Figure 7A) and a considerable
sensitization toward t-BHP, an inducer of oxidative stress (Fig-
ure 7D). This finding strongly supports a model of Brf2 as a key
human redox-sensor involved in the oxidative stress pathway
and mechanistically links its overexpression to malignancy, via
a mechanism that enables cancer cells to evade apoptosis in
conditions of prolonged oxidative stress, a hallmark of cancer
(Hanahan and Weinberg, 2000). In this context, ectopic overex-
pression of Brf2 in lung fibroblasts (Figures 7A–7C) and mam-
mary epithelial cells (Figure S5) reveals Brf2 oncogenic potential
under oxidative stress conditions, supporting its role as an onco-
genic driver in lung squamous cell carcinoma (Lockwood et al.,
2010) and breast cancer (Sanchez-Garcia et al., 2014). Whether
pro-apoptotic signals are generated exclusively in response to
decreased intracellular levels of SeCys tRNA or whether addi-
tional Brf2-dependent transcripts are involved in the process re-
mains to be determined.
The unexpected finding of Brf2 as a specialized Pol III TFIIB-
related factor with redox-sensing properties suggests that the
emergence and strict conservation of Brf2 in higher metazoans
has been evolutionary driven to uncouple the transcriptional
output of the Brf2-dependent promoters from the bulk of Pol III
transcription, in order to operate a stringent redox-dependent
control on a very small subset of Pol III genes. Since both sele-
noproteins and Brf2 are absent in lower eukaryotes such as
plants and fungi, evolution of a redox-dependent transcription
factor devoted to the transcription of SeCys tRNA must have
represented an important event during evolution of higher
complexity organisms.
EXPERIMENTAL PROCEDURES
A detailed description of protocols can be found in the Supplemental Experi-
mental Procedures.
Protein Expression and Purification
Brf2 lacking the Zn-ribbon/B-reader/B-linker (62–419, N-terminal His-tagged)
was co-expressed with a TBP-core construct (169–339) and used for struc-
tural determination. Full-length Brf2 (C-terminal His-tagged) was cloned into
pSBET and used for biochemical assays. The Quickchange Site-Directed
Mutagenesis kit (Agilent Technologies) was used to generate the Brf2 point
mutants.
Crystallization, Data Collection, Structure Solution, and Refinement
Complexes were assembled at a final concentration of 60 mM and crystals
were grown by mixing 1 ml each of complexes and crystallization solution
(10%–20% PEG 3350, 50–100 mMMgCl2, 2 mM DTT) in hanging drop plates.
Following harvesting and cryo-cooling, diffraction data were collected at the
Diamond Light Source (UK) and ESRF (France) synchrotrons. The structure
was solved by molecular replacement, using TFIIB-TBP/DNA (Protein Data
Bank: 1C9B) as the search model.
EMSAs
EMSAs where performed with 50-Cy5 fluorescently labeled oligonucleotides.
The gels were scanned with a Typhoon FLA9500 (GE Healthcare).
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Figure 7. Selenoproteins Levels and Resistance to Oxidative Stress Are Regulated in a Brf2-Dependent Manner
(A) Manipulation of Brf2 protein levels affects selenoproteins expression levels during oxidative stress in MRC5 and A549 cells. In the upper insets, a western blot
analysis of Nrf2 confirms induction of oxidative stress with 50 mM and 100 mM t-BHP in MRC5 and A549 cells, respectively. A western blot analysis of Brf2
immunoprecipitation from 107 MRC5 or A549 cells is shown in the lower insets (IP).
(B) Overexpression of Brf2 in MRC5 cells challenged with t-BHP results in decreased apoptosis as measured by FACS analysis via annexin V-FITC/PI staining.
The y axis represents the % of apoptotic cells, including both cells in early (annexin V-positive and PI-negative) and late (annexin V-positive and PI-positive)
apoptosis.
(C) Effects of overexpression of Brf2 wild-type andmutants on acquired resistance to apoptosis inMRC5 cells asmeasured by FACS analysis via annexin V-FITC/
PI staining. The y axis represents the % of apoptotic cells, including both cells in early (annexin V-positive and PI-negative) and late (annexin V-positive and
PI-positive) apoptosis.
(legend continued on next page)
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Brf2 Pull-Down Experiments
Pull-Down experiments were performed by incubation of bait and prey
proteins in binding buffer and loaded onto a His SpinTrap columns (GE
Healthcare). Following washing and elution, samples were analyzed by SDS-
PAGE.
Mass Spectrometry
Full-length Brf2 samples were digested with trypsin and infused into an LTQ
Velos Orbitrap mass spectrometer (Thermo Fisher Scientific) to characterize
cysteine oxidation states.
Fluorescence Polarization Assay
Binding of 50-Alexa488-labeled oligonucleotides were monitored at different
Brf2-TBP concentrations by fluorescence anisotropy at 25C on a POLARstar
Omega plate reader (BMG Labtech).
Immunopurification
Immunopurification from cells lysed in RIPA buffer were carried out using a
chip-grade Brf2 antibody (ab17011, Abcam) covalently coupled to epoxy-
magnetic beads (Life Technologies), according to themanufacturer’s protocol.
Brf2 Overexpression and siRNA
Cells were transfected with 1.5 mg of pCDNA3.1 (empty vector control),
Brf2WT-pCDNA3.1, Brf2C361A-pCDNA3.1, or Brf2C361D-pCDNA3.1 DNA
in a 6-well plate format, with Lipofectamine 2000 according to manufacturer’s
instructions. In Figures 7C and S5D, cells were transfected with 1.5 mg of
pCDNA3.1 (empty vector control) or 1.2 mg pCDNA3.1+ 0.3 mg of the relevant
Brf2 construct.
For Brf2 knockdown, cells were transfected with siGENOME Human Brf2
siRNA (M-013340-00-0005, Dharmacon) in Figures 7A and 7D, and with
siGENONE Human Brf2 siRNA (1) (D-013340-03-0010, Dharmcacon) or
siGENOME Human Brf2 siRNA (2) (D-013340-04-0010, Dharmacon) in Fig-
ure S6, using Lipofectamine 2000 (Life Technologies). Allstars negative control
(QIAGEN) was used for all control siRNA experiments.
qRT-PCR
Total RNA was extracted from treated cells with TRIzol reagent (Life Tech-
nologies) according to the manufacturer’s instructions. SeCys p-tRNA was
quantified using the relative standard curve method and the 5S rRNA as an
endogenous control. SeCys m-tRNA was monitored using a previously pub-
lished protocol (Honda et al., 2015) with minor modifications.
Flow Cytometry
Cell viability and apoptosis were assessed by flow cytometry using annexin V
and propidium iodide staining.
ACCESSION NUMBERS
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Supplemental Figures
Figure S1. General Conservation of the Architecture of TFIIB and TFIIB-like Factors, Related to Figure 1
(A) Schematic of the architecture of the Brf2-TBP/DNA complexes and sequences of the DNA scaffold used for crystallization.
(B) Superimposition of Brf2-TBP/DNA and TFIIB-TBP/DNA (PDB: 1C9B). The structures were superimposed using TBP as a template for structural alignment.
(C) Superimposition of the Brf2-TBP/U6-2 (blue), Brf2-TBP/TRNAU1 (grey) and Brf2-TBP/RPPH1 (green) structures. The structures were superimposed using
TBP as a template for structural alignment.
(D) Final electron density contoured at 1.2 s surrounding a tract of double-stranded DNA.
(E) Brf2 sequence conservation and domain organization of Homo sapiens (H.s.) Mus musculus (M.m.), and Danio rerio (D.r.).
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Figure S2. Sequence Alignments of Brf2 Promoters and Protein, Related to Figures 1 and 3
(A) Brf2-dependent promoters (40 nucleobase long centered around putative TATA boxes) were aligned using MEME (Bailey et al., 2009) by searching for a 16
nucleobase long consensus motif.
(B) Sequence and domain conservation between Brf2, Brf1 and TFIIB. Color-coding is as in Fig. 1. Brf2-Brf1 alignments are based on sequence conservation,
while Brf2-TFIIB is based on a structural alignment.
(C) Two views of the specific interaction of Brf2 R110 and A108with a TG (U6-2 in pale green) and TC (RPPH1 in light grey) dinucleotide step. In presence of the TG
sequence, the T on the nontemplate strand (in red) is left unstacked at its downstream edge. In presence of a TC sequence, no local distortions of the DNA are
observed. The two structures were superimposed by structurally aligning the Brf2 N-terminal cyclin repeats.
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Figure S3. Modular Functions of the Brf2 CTD, Related to Figures 4 and 5
(A) EMSA with serial Brf2 C-terminal deletion mutants showing that the region comprised between residues 289-311 of Brf2 is involved in direct binding to the
upstream transcription factor SNAPc.
(B) A conserved surface of TBP is utilized by different TBP associated factors. The TBP surface buried upon interaction with the associated factor is colored in
pink for human Brf2 (orange), in cyan for yeast Brf1 (PDB id: 1NGM, turquoise), in green for yeast TFIIA (PDB id: 1NH2, green) and in blue for yeast TAF1 (PDB id:
4B0A, blue).
(C) Structural conservation between Brf2 C361 part of the molecular pin, and C59 part of a short helical motif of the p-50 subunit of the NF-kB transcription factor
(PDB id: 1NFK).
(D) Brf2 oxidative-mimic mutation C361D does not hinder Brf2-TBP complex formation in absence of the DNA, as shown by pull-down assay. ‘‘IN’’ indicates the
input and ‘‘empty resin’’ the eluted untagged TBP binding non-specifically to the resin.
(E) EMSA shows that formation a functional Brf2-TBP/DNA complex is severely impaired in Brf2 oxidative-mimic mutant C361D. ‘‘IN’’ indicates the input and
‘‘empty resin’’ the eluted untagged TBP binding non-specifically to the resin.
(F) Fluorescence polarization saturation binding assay shows virtually no reduction in affinity of the Brf2 C361Amutant and an approximately 50-fold reduction in
affinity of Brf2 C361D mutant for TBP/DNA complexes.
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Figure S4. Mass Spectrometry Analysis of Brf2 Redox Modifications, Related to Figure 5
Biologically relevant oxidation states of C361 were confirmed by MS/MS as either unmodified, trapped with glutathione (-SS-Glu) or dimedone (Dmd). The
precursor ions, errors and ion scores are indicated below the annotated fragmentation mass spectra. For clarity, only prominent fragment ions are marked.
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Figure S5. Brf2 is a Redox Sensor in Living Cells, Related to Figures 6 and 7
(A) SeCys m-tRNA levels are reduced during oxidative stress in a Brf2-dependent manner, as monitored via four-leaf clover PCR (Honda et al., 2015). Samples
labeled empty vector and Brf2 represent transient over-expressions.
(B) Overexpression of Brf2 in MCF10A cells challenged with t-BHP results in decreased apoptosis as measured by FACs analysis via Annexin V-FITC/PI staining.
(C) Overexpression of Brf2 affects selenoproteins expression levels during oxidative stress in MCF10A cells.
(D) Effects of overexpression of Brf2 and Brf2 mutants on acquired resistance to apoptosis in MCF10A cells as measured by FACs analysis via Annexin V-FITC/PI
staining.
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Figure S6. Brf2-Dependent Reduction of SeCys p-tRNA and Enhanced Apoptosis in A549 Cells, Related to Figure 7
(A) Two individual Brf2 siRNAs cause a severe reduction of SeCys p-tRNA in A549 cells challenged with t-BHP, an effect that is fully rescued by concomitant
overexpression of a siRNA resistant form of Brf2.
(B) Two individual Brf2 siRNAs elicit a strong sensitization towards t-BHP in A549 cells, an effect that is fully rescued by concomitant overexpression of a siRNA
resistant form of Brf2.
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Figure S7. Mechanism of the Redox-Dependent Brf2 Blockade during Oxidative Stress and Carcinogenesis, Related to Figures 1, 2, 3, 4, 5, 6,
and 7
During normal growth conditions (A) Brf2- and Nrf2-dependent transcripts are synthesized at basal levels. Upon moderate oxidative stress (B), Nrf2 is activated
and Nrf2-dependent transcripts upregulated. Concomitantly, Brf2-dependent transcription, including SeCys tRNAs, is rapidly downregulated via redox-
dependent modifications of Brf2. The pre-existing pool of SeCys tRNA is sufficient to sustain synthesis of selenoproteins. Upon prolonged oxidative stress (C),
SeCys tRNA levels become limiting while, simultaneously, selenoprotein’s mRNAs continue to be highly upregulated by Nrf2. In this scenario, compromised
synthesis of selenoproteins drives the cells into apoptosis. In cancer cells (D), the Nrf2 pathway is constitutively activated and contributes to the observed
resistance of cancerous cells to higher than normal concentrations of reactive oxygen species. Under these circumstances, Brf2 overexpression is required to
overcome the innate redoxdependent blockade, ensuring elevated synthesis of SeCys tRNAs and, ultimately, enabling cancer cells to evade apoptosis under
prolonged oxidative stress.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Expression and purification of recombinant proteins.  
All proteins were expressed in Rosetta(DE3)pLysS. TB, and TBP-Brf2 complex were both expressed 
overnight at 20°C with 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) in TB medium. Full-length 
Brf2 was expressed at 30°C for 4 hours with 1 mM IPTG. Cells were grown at 37°C until the optical 
density reached 0.6 (A600), then the temperature was reduced and IPTG was then added 30 
minutes after. Cells were harvested by centrifugation at 4000g (20 minutes at 4°C) and the pellets 
stored at -80°C. For crystallization, pellets of Brf2 co-expressed with TBP were re-suspended in 750 
mM NaCl, 10 mM imidazole, 50 mM HEPES pH 7.9, 10% glycerol, 5 mM β-mercaptoethanol (buffer 
A1), supplemented with protease inhibitors tablets (Pierce) and DNase I (20 mg/ml). Cells were lysed 
through sonication and clarified by centrifugation (14000g for 45 minutes at 4°C). The supernatant 
was applied onto a 5 mL HisTrap HP column (GE healthcare) and bound proteins were washed with 
50 ml of buffer A1 supplemented with 50 mM imidazole, then eluted with buffer B1 (buffer A1 
containing 300 mM imidazole). The salt concentration was reduced to 350 mM by diluting the sample 
with buffer H1 (50 mM HEPES pH 7.9, 10% glycerol, 5 mM DTT). The proteins’s samples were 
loaded onto a 5 mL HiTrap Heparin HP column (GE Healthcare) and eluted with a 375 mM to 1.5 M 
NaCl gradient in 10 column volumes. At this stage, Brf2-TBP complex was dissociating and the 
subsequent steps were performed to purify Brf2 in isolation. The fractions containing the protein of 
interest were pooled and the N-terminal His-tag was cleaved overnight at 4°C with the 3C protease. 
Imidazole (20 mM) was added to the sample before loading onto a 5 ml HisTrap HP column. The 
flow-through was concentrated and applied onto a Superdex 200 26/600 column (GE Healthcare). 
The size exclusion chromatography was performed in a buffer containing 500 mM ammonium 
acetate, 50 mM HEPES pH 7.9, 10% glycerol and 2 mM DTT (gel filtration buffer). The fractions 
containing Brf2 were pooled, concentrated, flash-frozen and stored at -80°C. For full-length Brf2, the 
same protocol was used, with the exception that the tag was not cleaved and the second nickel 
column step was omitted. For experiments aiming to assess the effect of oxidative modifications on 
Brf2, DTT was removed from the buffer though a PD-10 desalting column (GE Healthcare) and the 
protein was immediately flash frozen.  
His-TBP pellets were re-suspended in buffer A2 (A1 buffer containing 500 mM NaCl) supplemented 
with protease inhibitors tablets (Pierce) and DNase I (20 mg/ml). Cell lysis and clarification were 
performed as mentioned above and the supernatant applied on a 5 ml HisTrap HP column (GE 
healthcare). The bound proteins were washed with 50 ml of buffer A2 supplemented with 50 mM 
imidazole, then eluted with buffer B2 (similar to buffer B1 but with 500 mM NaCl). The fractions 
containing His-TBP were pooled and loaded onto a 5mL HiTrap Heparin HP column (GE Healthcare). 
The protein was eluted with 500 mM to 2 M NaCl gradient in 10 column volumes. The tag was 
cleaved overnight at 4°C by addition of the 3C protease. The reaction was then adjusted to 20 mM  
imidazole and loaded onto a HisTrap HP column. The flow through was concentrated and loaded 
onto a Superdex 200 16/600 column (GE Healthcare) in gel filtration buffer. After elution, the protein 
was concentrated, flash frozen and stored at -80°C. SNAPc was expressed in insect cells and 
purified as described (Henry et al., 1998).  
Oligonucleotides.  
All oligonucleotides were purchased from Integrated DNA Technologies. Each single strand was re- 
suspended in 50 mM Tris pH 8.0, 5 mM MgCl2, 1 mM EDTA and mixed with the complementary 
strand in an equimolar ratio, heated at 95°C for 3 minutes. then allowed to cool down to room 
temperature overnight.   
Crystallization, data collection and processing.  
DNA sequences used for crystallization are described in Figure S1. The complexes were assembled 
at a final concentration of 60 µM with an equimolar ratio of TBP and Brf2 and 1.2 excess of the 
double stranded DNA. Crystals were grown by mixing 1 µL of the complexes and 1 µL of the 
crystallization solution (10-20% PEG 3350, 50-100 mM MgCl2, 2 mM DTT) in hanging drop plates. 
Seeds were introduced after 3 hours of equilibration. After 5 days, crystals were cryo-protected in a 
mix of 50% paraffin/50% paratone and flash frozen in liquid nitrogen. Initial data sets were collected 
at the ESRF (France) on ID29 and ID23eh1. The final high-resolution diffraction data were collected 
on beamlines I24 (U6) and IO3 (RPPH1 and TRNAU1) at Diamond Light Source (UK). The data were 
indexed with XDS (Kabsch, 2010), scaled and merged with SCALA (Evans, 2011) from the ccp4 
package (Winn et al., 2011). The data were processed using CC1/2 and completeness as cut-off 
criterion (Karplus and Diederichs, 2012).  
Structure determination and refinement.  
The structure of Brf2 bound to TBP and a U6 promoter was solved by molecular replacement using 
the TFIIB structure (PDB id: 1C9B) as a search model in PHASER (McCoy et al., 2007). The solution 
was confirmed by using a 2 ensemble search approach (first TBP and dsDNA then the cyclin repeats 
of TFIIB). The quality of the resulting electronic density did not allow the manual reconstruction 
directly after the molecular replacement. To improve the phases, solvent flattening and dummy atom 
building were carried out with DM (Cowtan, 2010) and ARP/wARP (Langer et al., 2008), respectively. 
The density modified maps clearly showed α-helices in the cyclin repeats region. Iterative manual 
building was performed with COOT (Emsley et al., 2010), and BUSTER-TNT (version 2.10.1) was 
used for refinement (Blanc et al., 2004). The U6-2 structure was used a search model for molecular 
replacement of RPPH1 and TRNAU1 structures. The quality of the final structures was assessed with 
MolProbity (Chen et al., 2010). Data collection and refinement statistics are shown in Table S2. The 
figures were prepared with PyMol (version 1.7.0.5 Schrödinger, LLC). The alignments were 
performed with Clustal Omega (Sievers and Higgins, 2014) and prepared with ESpript (Robert and 
Gouet, 2014).  
Electrophoretic mobility shift assay.  
The oligonucleotides used in this study are all Cy-5 labelled and based on the U6_2 sequence: 5'- 
C y 5 - A T T T G A T T G A A G G G C T T A A A A T A G G T G T G A C A G T A A C C - 3 ' a n d 5 ' - 
GGTTACTGTCACACCTATTTTAAGCCCTTCAATCAAAT-3'. The complexes were assembled in a 25 
µL reaction volume in a buffer containing 500 mM ammonium acetate, 50 mM HEPES pH 7.9, 10% 
glycerol with or without the addition of 5 mM DTT. The complexes were assembled by mixing 1 pmol 
of the dsDNA with 75 pmol of TBP and 25 pmol of Brf2 and incubated at room temperature for 1 hour. 
For the EMSAs in Figure 5, 10 pmol of Brf2, from which the DTT had been removed with a PD-10 
column, was pre-incubated with either H2O2, or oxidised/reduced glutathione (GSSG/GSH) gradients 
(3 m final) for 20 minutes at room temperature. Then 15 pmol of TBP and 1 pmol of dsDNA (with 1.1 
excess of labeled ssDNA) were added to a final volume of 25 µL. The incubation lasted for 20 
minutes. For the incubation with iodoacetamide, Brf2 (10 pmol) was first reduced with 0.5 mM DTT 
for 15 minutes, then the iodoacetamide was added at the final concentration indicated. The reaction 
was quenched after 30 minutes at room temperature with 50 mM DTT. TBP and the DNA were then 
added as previously described. For the time course experiment, 10 pmol of Brf2 were incubated at 
4°C for different time points, then TBP and the DNA were added. The binding reactions were resolved 
on a 4% polyacrylamide (37.5:1 acrylamide/bis-acrylamide, 10% glycerol, Tris borate EDTA 1X) gel in 
1X Tris- borate EDTA running buffer at 40 mA. The gels were then scanned with a Typhoon FLA 9500 
and band quantification was carried out with ImageQuanT TL version 8.1. The EMSA with SNAPc 
(Figure S3A) was performed as described previously (Saxena et al., 2005).  
Pull-downs.  
To study the interaction of Brf2 and TBP, 50 µg of Brf2 were loaded onto His SpinTrap columns (GE 
Healthcare) in presence or in absence of 100 µg of TBP, in a buffer containing 500 mM ammonium 
acetate, 50 mM HEPES pH 7.9, 10 mM imidazole, 10% glycerol and 2 mM β-mercaptoethanol in a 
total volume of 400 µL. The incubation was performed at 4°C for 2 hours. The beads were 
extensively washed with the same buffer supplemented with 50 mM imidazole. The proteins were 
eluted with 75 µL of the binding buffer containing 300 mM imidazole, boiled and analyzed on a SDS- 
PAGE.  
Fluorescence polarization assay.  
The oligonucleotides used for the fluorescence polarization studies, 5’-Alexa488- 
A T T G A A G G G C T T A A A A T A G G T G T G A C A G - 3 ’ a n d 5 ’ - 
GGTTACTGTCACACCTATTTTAAGCCCTTCAATCAAAT-3’, were purchased from Integrated DNA 
Technologies, annealed overnight as previously described. The TBP-DNA complex was assembled 
by saturating the oligonucleotides (100 nM final) with 250 mM final of TBP at room temperature for an 
hour in a volume of 5 µL. A serial dilution of Brf2 (from 10 mM to 5nM) was added and incubated for 
an extra hour at room temperature in 50 µL total reaction volume. The data were collected at 25°C on 
a POLARstar Omega plate reader (BMG Labtech), with excitation at 485 nm and emission at 520 nm, 
and analyzed with MARS Data Analysis Software version 2.10 R3 (BMG Labtech). The binding 
constants were calculated with GraphPad Prism 6. Three independent experiments were carried out 
in order to calculate standard deviation.  
Mass spectrometry.  
Solvents were purchased from Rathburn (Walkerburn, UK). All other reagents were purchased from 
Sigma unless otherwise stated. All the mass spectrometry experiments were performed with Brf2 full- 
length carrying a His-Tag at its C-terminus. Prior to treatment, the buffer was exchanged with PD-10 
columns (GE Healthcare) to have Brf2 in 50 mM HEPES pH 7.9 and 500 mM ammonium acetate. To 
check the different oxidative intermediates, Brf2 was incubated at room temperature for 1 hour with a) 
5 mM DTT, b) 3 mM of oxidized glutathione or c) overnight with 2 mM dimedone. Solutions of 10-20 
µM Brf2 were diluted 3-4 fold with 50 mM triethylammonium bicarbonate/5% acetonitrile and digested 
directly by addition of 20-50 ng trypsin and incubation for 1 hour at 37°C, followed by a second 
addition of 20-50 ng trypsin and incubation for a further 3 hours at 37°C. A 5 µL aliquot of each digest 
was injected directly for LC-MS analysis. Reversed phase chromatography was performed with an 
HP1200 platform (Agilent). Peptides were resolved on a 75 µm I.D. 15 cm C18 packed emitter 
column (3 µm particle size; Nikkyo Technos) over 30 minutes using a linear gradient of 96:4 to 50:50 
buffer A:B (buffer A: 1% acetonitrile/3% dimethyl sulfoxide/0.1% formic acid; buffer B: 80% 
acetonitrile/3% dimethyl sulfoxide/0.1% formic acid) at 250 nL/minute. Peptides were ionised by 
electrospray ionisation with 1.8 kV applied immediately pre-column via a microtee built into the 
nanospray source. Sample was infused into an LTQ Velos Orbitrap mass spectrometer (Thermo 
Fisher Scientific) directly from the end of the tapered tip silica column (6-8 µm exit bore). The ion 
transfer tube was heated to 275°C and the S-lens set to 60%. MS/MS were acquired using data 
dependent acquisition based on a full 30,000 resolution FT-MS scan with preview mode disabled and 
internal lock mass calibration against ion 401.922718. The top 10 most intense ions were fragmented 
by collision-induced dissociation and analyzed with enhanced ion trap scans. Precursor ions with 
unknown or single charge states were excluded from selection. Automatic gain control was set to 
1,000,000 for FT-MS and 30,000 for IT-MS/MS, full FT-MS maximum inject time was 500 ms and 
normalized collision energy was set to 35% with an activation time of 10 ms. Wideband activation 
was used to co-fragment precursor ions undergoing neutral loss of up to -20 m/z from the parent ion, 
including loss of water/ammonia. MS/MS was acquired for selected precursor ions with a single 
repeat count acquired after 5 seconds delay followed by dynamic exclusion with a 10 ppm mass 
window for 10 seconds based on a maximal exclusion list of 500 entries. Raw MS/MS data was 
compiled and interrogated against the swissprot 2011_01 human database, customized to include the  
Brf2 construct sequence, with Proteome Discoverer v1.4 and Mascot v2.3. The Mascot search 
parameters used were: 10 ppm precursor peptide mass error, 0.25 Da fragment mass error, and 
trypsin specificity with up to two missed cleavages.  
Cell culture.  
MRC5 and A549 cell lines (ATCC, UK) were maintained and grown in EMEM (ATCC, UK) and Hams 
F-12 (Kaighn’s) media (Life technologies, CA, USA) respectively, and supplemented with 10% (v/v) 
FBS (Life technologies) and 100 U/ml penicillin and streptomycin (Sigma). MCF10A (ATCC, UK) were 
maintained in DMEM/F12 (Life technologies, CA, USA) and supplemented with 5% (v/v) donor horse 
serum (16050122, Life technologies), Insulin (10 µg/ml, I9278, sigma), cholera toxin (100 ng/ml, 
C8052, Sigma), EGF (20 ng/ml, AF-100-15, Peprotech), Hydrocortisone (0.5 mg/ml, H6909, Sigma) 
and 100 U/ml penicillin and streptomycin. All cells were grown at 37°C in a 5% CO2 humidified 
atmosphere. Cells were treated with varying concentrations of t-BHP (Sigma, St Louis, MA, USA) in 
the conditioned medium and subsequently lysed with RIPA lysis buffer (50 mM Tris pH 8.0, 150 mM 
NaCl, 1% (v/v) NP40, 0.5% (v/v) Sodium deoxycholate, 2 mM EDTA) containing protease inhibitors 
(Pierce).    
Immunoprecipitation.  
Brf2 antibodies (ab17011, Abcam) were coupled to magnetic beads using the DynaBeads Antibody 
coupling kit (Life Technologies) according to the manufacturer’s protocol. After lysis and 
centrifugation, the protein concentration in the supernatant was measured with Bradford Protein 
Assay (Bio-Rad) to ensure that the same amount of total proteins was incubated with the beads. The 
cell lysates were then incubated overnight at 4°C. Immunoprecipitates were extensively washed with 
lysis buffer and eluted with SDS loading buffer by heating at 50°C for 10 minutes.  
Quantitative RT-PCR.  
Total RNA was extracted from treated cells with TRIzol reagent (Life technologies) according to 
manufacturer’s instructions. The Quantitect reverse transcription kit (Qiagen, Netherlands) was used 
to synthesize cDNA following manufacturers instructions, except for a 10 minutes incubation step at 
70°C before addition of the polymerase to the reaction. To determine levels of selenocysteine 
precursors and mature tRNA, RPPH1 (PPH68975A-200, Qiagen), RNA7SK (PPH68975A-200, 
Qiagen), U6, tRNA Leu and 5S rRNA, syber green assays were performed. Primers 1) 5’- 
TCAGTGGTCTGGGGTGCAGG-3’ and, 2) 5’- GTCCGGTTCGATAAGTAAGATTTAAGGC-3’ were 
used to determine selenocysteine tRNA precursor levels. Primers 1) 5’-GCACCCCAGACCACTGAG 
GA-3’ and Primers 2) 5’-AGCGACAGAGTGGTTCAATTCCAC-3’ were used to determine mature 
selenocysteine tRNA levels. Primers 1) 5’-GGCCATACCACCCTGAACGC-3’ and 2) 5’- 
CAGCACCCGGTATTCCCAGG-3 were used to determine 5S rRNA levels, the reference transcript 
for all syber green assays (loading control). Primers used to determine levels of U6 were 1) 5’- 
G G A A C T C G A G T T T G C G T G T C A T C C T T G C G C - 3 2 ) 5 ’ - 
G G A AT C TA G A A C ATATA C TA A A AT T G G A A C - 3 ’ a n d t R N A L e u w e r e 1 ) 5 ’ - 
GTCAGGATGGCCGAGTGGTCTAA-3’ 2) 5’-TGTCAGAAGTGGGATTCGAACCCAC-3’. Amplification 
of cDNA was performed in a 20 µl reaction containing either 1) PerfeCTa SYBR Green FastMix 
(VWR, Radnor, USA), 0.3 µM of syber green primers mentioned above, and cDNA, (22.5 and 15 ng 
to detect selenocysteine tRNA precursor and mature levels resepctively and 7.5 ng of cDNA for other 
RNA levels). RT-PCR was performed with the Applied Biosystems 7900HT Fast Real time PCR 
system and the samples were subjected to an initial denaturation step at 95°C for 10 minutes, 
followed by 40-cycles of 95°C for 20s, 60°C for 20s, and 72°C for 20s. All RNA levels were quantified 
with the relative standard curve method and the Brf1-dependent 5S rRNA as an internal control. 
Mature selenocysteine tRNA levels were quantified using the comparative Ct method and 5S rRNA 
as internal control. Prism 6  was used to perform unpaired t-test statistical analysis to determine p 
values. P values < 0.05 were deemed significant and data shown is from three biological repeats.  
Flow cytometry.  
Cells were trypsinized and re-suspended in media containing 1 µg mL-1 of Propidium iodide (Sigma), 
5 µL per well of FITC-Annexin V (BD Biosciences) and 2.5 mM CaCl2. Cells were then analyzed by 
flow cytometry on a LSR II SPOC instrument (BD Biosciences).   
Western Blot.  
Proteins were separated via SDS-PAGE and transferred to a nitrocellulose membrane (GE- 
Healthcare). The membrane was then blocked for 1 hour in protein-free RotiBlock buffer (Carl Roth, 
Germany) and then incubated for 1 hour at room temperature with primary antibodies for anti-BRF2 
(ab17011, 1:1000, Abcam), anti-beta Actin (ab6276, 1:5000, Abcam) or anti-Glutathione (ab19534, 
1:1000, Abcam) diluted in RotiBlock buffer. In the case of anti-GPX1 (ab50427, 1:500, Abcam), anti- 
GPX2 (ab137431, 1:1000, Abcam), anti-GPX4 (ab125066, 1:1000, Abcam), anti-SEP15 (ab124840, 
1:1000, Abcam), anti-SelM (ab133681, 1:1000 Abcam), anti-Nrf2 (ab62352, 1:1000, Abcam) primary 
incubations were performed overnight at 4°C in 5% (w/v) BSA TBS-T. The membranes were then 
washed with TBST three times, followed by incubation with either rabbit anti Goat IgG-HRP (sc-2768, 
1:5000, Santa Cruz Biotechnology, Santa Cruz USA), ECL peroxidase labelled anti-mouse (NA931, 
1:5000, VWR) or anti-rabbit (NA931, 1:5000, VWR), and then developed.  
  
Table S1, Related to Figure 1: Actively transcribed Brf2-dependent genes. 
 
Name of gene Description Genome location Function 
RMRP RNA component of mitochondrial RNA processing endoribonuclease 
NC_000009.12 
/9p21-p12 
Mitochondrial RNA 
processing 
RN7SK RNA polymerase II regulation NC_000006.12 /6p12.2 
P-TEFb (RNA Pol II 
elongation) inhibition  
RNU6 (U6-1) Component of the spliceosome, catalytic RNA 
NC_000015.10 
/15q23 RNA processing 
RNU6 (U6-2) Component of the spliceosome, catalytic RNA 19p13.3 RNA processing 
RNU6 (U6-7) Component of the spliceosome, catalytic RNA 
NC_000014.9 
/14q12 RNA processing 
RNU6 (U6-8) Component of the spliceosome, catalytic RNA 
NC_000014.9 
/14q12 RNA processing 
RNU6 (U6-9) Component of the spliceosome, catalytic RNA 
NC_000019.10 
/19p13.3 RNA processing 
RNU6ATAC Component of the  minor spliceosome 
NC_000009.12 
/9q34.2 RNA processing 
RNY1 
Component of the 
ribonucleoproteins Ro, implications 
in DNA replication 
NC_000007.14 
/7q36 DNA replication 
RNY3 
Component of the 
ribonucleoproteins Ro, implications 
in DNA replication 
NC_000007.14 
/7q36 DNA replication 
RNY4 
Component of the 
ribonucleoproteins Ro, implications 
in DNA replication 
NC_000007.14 
/7q36 DNA replication 
RNY5 
Component of the 
ribonucleoproteins Ro, implicated 
in DNA replication 
NC_000007.14 
/7q36 DNA replication 
RPPH1 Component of the RNase P, implicated in tRNA maturation 
NC_000014.9/ 
14q11.2 5’-tRNA processing 
TRNAU1 Selenocysteine tRNA NC_000019.10/ 19q13.2-q13.3 
Translation of 
selenoproteins 
Table S2, Related to Figure 1: Data collection and refinement statistics  
 U6 #2 RPPH1 TRNAU 
Data collection    
Space group P212121 P212121 P212121 
Cell dimensions      
    a, b, c (Å) 77.3 89.9 102.5 77.7 91.9 102.4 77.0 91.3 102.9 
    a, b, g  (°)  90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 
Resolution (Å) 29.5-1.9 (2.0-1.9) * 30-2.2 (2.3-2.2) * 30-2.7 (2.85-2.7) * 
Rmerge 0.058 (3.19) * 0.069 (1.617) * 0.157 (2.216) * 
I/sI 11.2 (0.5) * 13.9 (0.8) * 6.9 (0.9) * 
Completeness (%) 99.3 (99.3) * 99.7 (98.7) * 98.9 (99.4) * 
Redundancy 4.2 (4.2) * 5.3 (4.3) * 4.8 (5.0) * 
CC1/2 
 
0.999 (0.287) * 0.999 (0.367) * 0.992 (0.312) * 
 
Refinement    
Resolution (Å) 29.5-1.9 29.7-2.2 29.7-2.7 
No. reflections 56427 199497 20221 
Rwork/ Rfree (%) 18.6/21.6 23.6/25.8 21.4/24.9 
No. atoms    
    Protein 3832 3826 3798 
    DNA 1101 1088 1122 
    Water 388 201 141 
B-factors    
    Protein 56.9 68.0 79.8 
    DNA 79.9 86.3 90.5 
    Water 58.8 59.4 60.5 
R.m.s deviations    
    Bond lengths (Å)  0.010 0.009 0.010 
    Bond angles (º) 0.94 0.96 0.99 
*Highest resolution shell is shown in parenthesis.  
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